Targets › CIITA
2 programs from 1 company in 2 trials: 2 Phase 1; Genitourinary, Oncology; next expected readout Dec 2027.
Essential for transcriptional activity of the HLA class II promoter; activation is via the proximal promoter. Does not bind DNA. May act in a coactivator-like fashion through protein-protein interactions by contacting factors binding to the proximal MHC class II promoter, to elements of the transcription machinery, or both PubMed:8402893, PubMed:7749984,. Alternatively it may activate HLA class II transcription by…. (UniProt, P33076)
Open in Phaseline: the race on CIITA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC | Ex Vivo CRISPR-Cas9 Gene Editing of Donor Kidney CRISPR-Cas9 ribonucleoprotein complexes targeting HLA-A, HLA-B, and CIITA to knock out HLA | HLA-A, HLA-B, CIITA | Phase 1 | End-Stage Renal Disease | Dec 2027 |
| AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC | Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver CRISPR-Cas9 RNP complex targeting HLA-A, HLA-B, and CIITA to create hypoimmunogenic graft | HLA-A, HLA-B, CIITA | Phase 1 | Liver Diseases | Dec 2027 |
End-Stage Renal Disease (1) Liver Diseases (1)
other (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.